Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2024-04-18
2024-08-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation of Exercise Training-Induced Myokines and Adipolkines in Humans
NCT03037216
MyoGene: Effects of Acute Exercise on (Myokine) Gene Expression in Human Skeletal Muscle
NCT01316731
The Effects of Exercise of Secreted Factors From Muscle and Adipose Tissue
NCT02565823
Exercise Regulation of Human Adipose Tissue
NCT03133156
Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation (Columbus)
NCT01911091
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For the first in-person visit, participants will arrive to The Rockefeller University Hospital between 8:00am to 10:00am in a non-fasted state. All participants will be asked to keep track of their food consumption both the night prior to and the day of the visit. Participants will be asked to consume their breakfast 2-hours prior to arrival, and will be asked to eat their habitual breakfast. Participants will be asked to refrain from intense physical activity 48 hours prior to the testing day, any caffeinated beverages the day of arrival, and any alcoholic beverages for 24-hours prior to arrival.
Height, weight, resting heart rate, blood pressure, and body composition, will be measured. Blood will be collected from the upper arm for blood chemistry analyses including HbA1c (%), Cholesterol (mg/dl), LDL-cholesterol (mg/dl), HDL-cholesterol (mg/dl), Triglyceride (mg/dl), Complete blood count (CBC), and High sensitivity C-reactive protein (hsCRP). An additional 20mL of blood will be drawn from the arm for protein identification through the use of proteomics. Subcutaneous adipose from the lower abdomen will be collected following blood collection.
Following a minimum of one week from fat sample collection, participants will take part in a maximal aerobic consumption (VO2max) test between 8:00am-10:00am. Participants will arrive in a non-fasted state, but all participants will be asked to keep track of their food consumption the night prior to, and the morning of, the VO2max test. When possible, the investigators will recommend the participants to consume the identical dinner/breakfast to that consumed prior to the first in-person visit. Participants will be asked to consume their breakfast 2-hours prior to arrival. Additionally, participants will be asked to refrain from intense physical activity 48 hours prior to the testing day, any caffeinated beverages the day of arrival, and any alcoholic beverages for 24-hours prior to arrival.
For VO2max testing, participants will take part in a general warm up consisting of walking on a motorized treadmill for 5 minutes followed by performing a graded exercise test (GXT) on a motorized treadmill while wearing a one-way, non-rebreathing Hans Rudolph 7450 series V2 mask that allows for the evaluation of all expired air which is calibrated prior to each test. Volume of ventilated expired air as well as oxygen and carbon dioxide concentrations of expired air will be determined using a commercial metabolic cart (Parvo Medics' TrueOne® 2400, Parvo, UT). Specifically, the investigators will incorporate the Ellestad Protocol to determine the participants VO2max. The Ellestad Protocol is divided into 8 phases which gradually increases in speed and incline throughout the test. To confirm that the VO2max test is eliciting a metabolic response, lactate measurements through the use of a finger prick will be taken both before and immediately following the exercise test. Additionally, participants will wear a light-weight heart rate monitoring device (Polar) strapped around the upper torso during testing to track heart rate throughout exercise.
The VO2max test will continue until the participant reaches volitional fatigue defined by reaching a rate of perceived exertion (RPE) greater than 19 (using the Borg RPE Scale), OR a respiratory exchange ratio (RER) reaching above 1.1, OR a participant choosing to cease exercise for any reason.
Blood will be collected from the arm immediately following exercise, 1-hour following the exercise, and 3-hours following exercise. Adipose will be collected Immediately following the final blood draw, participants will be prepped for adipose tissue collection (from the abdominal subcutaneous adipose). This will occur 3-hours following exercise.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Secretome characterization and signaling to the adipose tissue
To identify possible exercise stimulated secreted proteins which signal to the adipose tissue, subcutaneous adipose and blood will be collected both before and at multiple timepoints following a VO2max test. Adipose will be collected from the abdominal subcutaneous region and blood will be collected from the arm. Blood will be analyzed for change in protein abundance and adipose will be analyzed for change in gene expression.
Exercise
Participants will take part in a VO2max test. This will include a graded exercise test (GXT) on a motorized treadmill while wearing a one-way, non-rebreathing valve and nose clip that allows for the evaluation of all expired air. Specifically, we will incorporate the Ellestad Protocol. The Ellestad Protocol is divided into 8 phases which gradually increases in speed and incline throughout the test. The VO2max test will continue until the participant reaches volitional fatigue defined by reaching a rate of perceived exertion (RPE) greater than 19 (using the Borg RPE Scale), OR a respiratory exchange ratio (RER) reaching above 1.1, OR a participant choosing to cease exercise for any reason.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise
Participants will take part in a VO2max test. This will include a graded exercise test (GXT) on a motorized treadmill while wearing a one-way, non-rebreathing valve and nose clip that allows for the evaluation of all expired air. Specifically, we will incorporate the Ellestad Protocol. The Ellestad Protocol is divided into 8 phases which gradually increases in speed and incline throughout the test. The VO2max test will continue until the participant reaches volitional fatigue defined by reaching a rate of perceived exertion (RPE) greater than 19 (using the Borg RPE Scale), OR a respiratory exchange ratio (RER) reaching above 1.1, OR a participant choosing to cease exercise for any reason.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* being between the ages of 18-45
* being moderately active (defined as participating in 30 minutes of recreational activity at least once per week for the past 3 months but no more than 3 times per week)
* non-smoking
* free of metabolic or cardiovascular diseases
Exclusion Criteria
* thrombophlebitis (blood clots)
* recent surgery of the upper or lower extremities (any surgeries in past 6 months at the ankle or foot, or in the past year at the knee, hip, shoulder or elbow)
* recent uncontrolled bruising
* recent muscle, bone or joint damage which interferes with regular physical activity
* taking part in vigorous physical activity more than 3 times per week
* any prior sensations of chest pain during exercise.
* individuals who are pregnant as determined by an on-site pregnancy test
* individuals who are currently taking exogenous hormones
* individuals who chronically consume NSAIDS or other anti-inflammatory medication (every day for the previous 3 months)
* failing the PARQ questionnaire as indicated by answering "YES" to any of the questions
* Having a BMI \>32
* Any medical condition that in the opinion of the investigator will confound interpretation of data for analysis.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital for Special Surgery, New York
OTHER
Rockefeller University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luke Olsen, PhD
Role: PRINCIPAL_INVESTIGATOR
The Rockefeller University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rockefeller University
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Walker JM, Garcet S, Aleman JO, Mason CE, Danko D, Butler D, Zuffa S, Swann JR, Krueger J, Breslow JL, Holt PR. Obesity and ethnicity alter gene expression in skin. Sci Rep. 2020 Aug 21;10(1):14079. doi: 10.1038/s41598-020-70244-2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LOL-1044
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.